Billionaire John Paulson’s Latest Stock Picks

One of the most revered names in the business, billionaire hedge fund manager John Paulson is famous for his lucrative bets against subprime mortgages in the mid-2000s. Paulson earned a $4.9 billion payout in 2010, breaking records in the hedge fund industry. Lately, however, Paulson has had to convince investors that his fund is still on the straight and narrow path—his major funds posted double-digit losses over the past year and change. The fund’s economic outlook in 2011 was rather sunny, costing the fund billions as it took on significant amounts of risk in its investments.

largest hedge funds in the worldWe will take a look here at how Paulson’s major stock picks, as disclosed in Paulson & Co.’s 13F regulatory filing, compare to his past filings, particularly looking at major up and down movements in the portfolio.

Gold is still king. John Paulson continues to load quite a bit of his portfolio with gold-related equities. His SPDR Gold Trust (NYSEARCA:GLD) is valued at $3.7 billion dollars, or about a quarter of the total value of his 13F portfolio. But that’s not all: the top equity holding in the portfolio remains AngloGold Ashanti Limited (NYSE:AU), which, along with convertible bond issues, totals slightly over $1 billion. We explained that, in the wake of the third round of quantitative easing (QE3), gold and a variety of different commodities make ideal hedges against currency debasement and inflation. Essentially, Paulson has put his chips down on a gold ETF and a gold production company—two ways to play gold that have underperformed buying physical gold since the beginning of the year. AngloGold is down 35 percent year-over-year, and we note that it derives its revenue not only from gold but also from silver, sulfuric acid, and uranium production. The company produced about 4.3 million ounces of gold in 2011, and though its performance has not been inspiring over the past year, we are more optimistic about demand levels for gold going forward as gold becomes a more common monetary reserve asset.

More lightweight on Hartford and Delphi. Paulson’s fund decreased its holdings in Delphi Automotive PLC (NYSE:DLPH), which Paulson initiated as a top 5 holding in the fourth quarter 2011. Since the beginning of 2012, shares of the company are up 47 percent. The company issued a positive third-quarter earnings report of 84 cents per share, up from 79 cents from a year ago. This comes, however, as top line growth is starting to pressure earnings (revenue fell 6 percent) and as the company begins significant strategic readjustments in the slow European markets, so Paulson’s move to take profits here makes sense. Paulson still has a significant stake in the company, though, and other optimists like billionaire hedge fund manager Steven Cohen are also keen on Delphi and the automotive industry generally, as we noted in a previous article.

Paulson also cashed in nearly 12 million shares of Hartford Financial Services Group Inc (NYSE:HIG), a major insurance provider for individuals and businesses in the United States. With shares of the company up about 26 percent year-to-date, we also see a rationale for profit-taking in this still sizable holding. However, Hartford still looks like a good value play according to historical valuations. Shares are trading at about 6 times forward consensus earnings estimates, which is well below the 10-year range of 7 to 28. Shares are trading at their lowest valuations on a P/E basis since 2002. If you add in a successful reconstruction—which is already well underway—we could see a significant bump in Hartford shares.

More heavyweight in technology. Paulson’s portfolio has beefed up some of its top 10 technology holdings. Particularly, his holdings of Life Technologies Corp. (NASDAQ:LIFE) have increased to 13.5 million shares valued at a total $660 million. Another mid-cap like Delphi, Hartford, and AngloGold Ashanti, Life Technologies Corp. produces a number of specialty products for use the life sciences and life science research. Up 18 percent year-to-date, shares are still only trading at 11 times forward consensus earnings, and Paulson likely sees several catalysts for growth. The company stands to make considerable headway in genomics and molecular diagnostics markets, though, as S&P notes, its next-generation sequencing platform SOLiD sells a significantly higher price point than that of many of its major competitors. Illumina, Inc. (NASDAQ:ILMN) is also expected to come out with a sequencing platform by year’s end, adding to competition in this area—a source of caution for investors.

Computer and internet technology firm Equinix Inc (NASDAQ:EQIX) also received a significant boost in Paulson’s portfolio for the third quarter; Paulson doubled his stake. Having peaked at the end of September, shares of the company have since retreated slightly to around $170 per share. Tech hedge fund guru Philippe Laffont remarked that Equinix Inc has the equivalent of “beach-front property” in the worldwide internet infrastructure (view Laffont’s portfolio here). The recent dip in the company’s shares might be an opportunity to take advantage of the secular growth in internet infrastructure services and solutions.

In the rough waters ahead for the stock market—the fiscal cliff, wavering European and U.S. economies, and mixed earnings reports—John Paulson is definitely a person to keep an eye on amidst the choppy waves. Despite his funds’ mediocre performance over the past two years, we could yet see the same virtuosity that led Paulson’s funds to record returns from 2007 to 2010.

Disclosures: Nothing to report.

Biotech Insider Alert - $6 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The Oldest Money Managers

The Greatest Directors in the World

Largest Animals in the World

World’s Most Expensive Desserts

Best Selling Comic Books of All Time

A-list Actors who Sabotaged Their Career

Rappers With a College Degree

The Best Jazz Albums of all Time

The Most Influential Jazz Musicians

The World’s Most Famous Photographers

The Best Oscar-Winning Songs

Most Influential Choreographers Ever

Most Expensive Department Stores in the World

The Most Expensive Stolen Paintings in the World

The World’s Most Expensive Teas

Top Oscar Record Holders

The Most Expensive Flowers in the World

Countries With a Booming Film Industry

Most Expensive Cupcakes in the World

Uncommon European Escapes

The Most Stolen Artists in History

Best Travel Destinations in Australia

World’s Most Expensive Musical Instruments

World’s Most Famous Animals

Most Expensive Cakes in the World

Most Expensive Kosher Champagne in the World

Most Expensive Kosher Wine in the World

The Most Surprisingly Dark Fairy Tales

Most Popular Travel Destinations in Asia

The 10 Most Expensive Dresses Ever Worn to the Oscars

World’s Most Visited Art Museums

Best Countries for Photographers to Work in

Best Paid Jobs in the Film Industry

The Most Renowned Recovered Paintings Ever

Child Stars That Turned out Just Fine

Books That Were Banned in the Past Century

World’s Richest Dancers

Best Remedies against Bad Breath

Foods That Improve Your Skin Texture

Best-Selling Children’s Books of all Time

Foods That Boost Your Libido

Best-Selling Books of all Time

The Most Expensive Academy Awards Jewelry in History

Most Expensive Japanese Restaurant In New York City

The Best B-Boy Movies

Most Awesome Hip Hop Documentaries

Foods That Stain Your Teeth

Richest Doctors in the World

The Best Movie Sountracks Ever

The Highest Grossing Musicals on Broadway

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!